Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19—A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium

Chou, Stanley S.; Beghi, Ettore; Helbok, Raimund; Moro, Elena; Sampson, Joshua N.; Altamirano, Valeria; Mainali, Shraddha; Bassetti, Claudio; Suárez, José I.; McNett, Molly

doi:10.1001/jamanetworkopen.2021.12131

Cited by 319 publications

(293 citation statements)

References 50 publications

Supporting

Mentioning

248

Contrasting

Unclassified

Order By: Relevance

“…The incidences of at least one new-onset neurological signs/symptoms in the context of COVID-19 infection were extremely wide-ranging, i.e., ~ 12 to ~ 85%. The wide extent of these percentages was based on retrospective and prospective studies from various countries: Austria (Zifko et al 2021); China (Mao et al 2020;Xiong et al 2020) Egypt (Khedr et al 2021); Iran (Amanat et al 2021;Ghaffari et al 2021); Italy (Benussi et al 2020;Rifino et al 2021;Travi et al 2021); France (Kremer et al 2020); Germany (Fleischer et al 2021); Mexico (Flores-Silva et al 2021); Pakistan (Iltaf et al 2020); Poland (Wnuk et al 2021); Portugal (Oliveira et al 2021); South Korea (Kim et al 2021);Spain (García-Azorín et al 2021a, b;García-Moncó et al 2020;García-Azorín et al 2021a, b;Romero-Sánchez et al 2020); Turkey (Karadaş et al 2020;Yuksel et al 2021); United States of America (Chachkhiani et al 2020;Eskandar et al 2021;Frontera et al 2021;Liotta et al 2020); multinational (Chou et al 2021). Systematic reviews with or without meta-analysis (Cagnazzo et al 2021;Chua et al 2020;Collantes et al 2021;Pinzon et al 2020;Romoli et al 2020;Tsai et al 2020;Vakili et al 2021) and narrative/ scoping reviews (Ahmed et al 2020;Maury et al 2021;Roy et al 2021...…”

Section: Discussionmentioning

confidence: 99%

COVID-19 outcomes of 10,881 patients: retrospective study of neurological symptoms and associated manifestations (Philippine CORONA Study)

Espiritu

Anlacan

et al. 2021

J Neural Transm

View full text Add to dashboard Cite

Our study aimed to determine the effects of new-onset neurological symptoms (NNS) on clinically relevant outcomes in hospitalized patients with COVID-19 infection. We conducted a nationwide, comparative, retrospective, cohort study among adult, hospitalized COVID-19 patients involving 37 hospital sites from various regions in the Philippines. We included a total of 10,881 patients with confirmed COVID-19 infection (2008 had NNS while 8873 did not have NNS). The adjusted hazard ratios (aHRs) for mortality among the mild and severe cases were significantly higher by 1.660 (95% CI 1.132–2.435) and by 1.352 (95% CI 1.042–1.752), respectively, in the NNS group compared to those in the non-NNS group. The aHRs for respiratory failure in the NNS group were significantly increased by 1.914 (95% CI 1.346–2.722), by 1.614 (95% CI 1.260–2.068), and by 1.234 (95% CI 1.089–1.398) among the mild, severe, and critical cases, respectively. The aHRs for ICU admission in the NNS group were still significantly higher by 1.973 (95% CI 1.457–2.673) and by 1.831 (95% CI 1.506–2.226) among the mild and severe cases, respectively. Patients who had NNS were not significantly associated with a longer duration of ventilator dependence (adjusted odds ratio (aOR) 0.954, 95% CI 0.772–1.179), longer ICU stay (aOR 0.983, 95% CI 0.772–1.252) and longer hospital admission (aOR 1.045, 95% CI 0.947–1.153). The presence of NNS significantly increases the risk of mortality, respiratory failure and ICU admission among COVID-19 patients. Registration and associated protocol publication: ClinicalTrials.gov website (NCT04386083); Espiritu AI, Sy MCC, Anlacan VMM, Jamora RDG. The Philippine COVID-19 Outcomes: a Retrospective study Of Neurological manifestations and Associated symptoms (The Philippine CORONA study): a protocol study. BMJ Open. 2020;10:e040944.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 outcomes of 10,881 patients: retrospective study of neurological symptoms and associated manifestations (Philippine CORONA Study)

Espiritu

Anlacan

et al. 2021

J Neural Transm

View full text Add to dashboard Cite

show abstract

“…Furthermore, a small cohort study reported that there was a 2.5 times higher incidence measure of COVID-19 in patients with MS compared to the general population [37]. A recent global cohort study (representing 13 countries and 4 continents) reported neurological symptoms, including headache and anosmia, in COVID-19 patients, and those patients with clinical neurological symptoms were more susceptible to in-hospital death [38]. In contrast, two independent studies reported that patients with MS are less likely to be susceptible to COVID-19 infection [39,40].…”

Section: Multiple Sclerosis (Ms)mentioning

confidence: 99%

COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies

2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the coronavirus disease 2019 (COVID-19) pandemic, which has been a topic of major concern for global human health. The challenge to restrain the COVID-19 pandemic is further compounded by the emergence of several SARS-CoV-2 variants viz. B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma) and B.1.617.2 (Delta), which show increased transmissibility and resistance towards vaccines and therapies. Importantly, there is convincing evidence of increased susceptibility to SARS-CoV-2 infection among individuals with dysregulated immune response and comorbidities. Herein, we provide a comprehensive perspective regarding vulnerability of SARS-CoV-2 infection in patients with underlying medical comorbidities. We discuss ongoing vaccine (mRNA, protein-based, viral vector-based, etc.) and therapeutic (monoclonal antibodies, small molecules, plasma therapy, etc.) modalities designed to curb the COVID-19 pandemic. We also discuss in detail, the challenges posed by different SARS-CoV-2 variants of concern (VOC) identified across the globe and their effects on therapeutic and prophylactic interventions.

show abstract

“… 1 , 2 , 3 , 4 , 6 , 9 Also, neurological symptoms have been reported in patients with COVID‐19. 11 , 14 , 42 Thus, it will be interesting to assess the long‐term effects of COVID‐19 in patients with mental diseases.…”

Section: Discussionmentioning

confidence: 99%

Patients with schizophrenia have decreased COVID‐19 prevalence among hospitalised patients with psychiatric and neurological diseases: A retrospective analysis in Mexican population

Rivas-Ramírez¹,

Tendilla-Beltrán

Gómez-Mendoza³

et al. 2021

Int J Clin Pract

View full text Add to dashboard Cite

Background Increased coronavirus disease 2019 (COVID‐19) incidence and mortality in hospitalised patients with psychiatric and neurologic disorders have been reported. Methods The clinical records of 198 patients with psychiatric and neurological disorders hospitalised in the Dr Rafael Serrano Psychiatric Hospital in Puebla during the peak of the first wave of the COVID‐19 pandemic in Mexico were analysed for psychiatric or neurologic diagnosis, gender, age, medical diagnosis, and COVID‐19 prevalence. For patients with COVID‐19, the effects of gender, and medical diagnosis were explored. Results There was an increased COVID‐19 prevalence in the studied population (43.94%), compared with the national Mexican (~0.21% to 0.63%) and worldwide average in the general population (~0.13% to 4.28%). However, the mortality rate (5.75%) was lower than that reported in Mexico (11.28%‐13.55%), which was higher than the worldwide average (2.95%‐4.98%). We detected increased COVID‐19 prevalence in patients with comorbidities (odds ratios [OR] 0.4; 95% CI: 0.2‐1, P = .0447). Moreover, patients with schizophrenia spectrum disorders have a decreased predisposition to COVID‐19 (OR 0.4, 95% CI: 0.2‐0.8; P = .0250), as opposed to patients with intellectual disability that are predisposed to COVID‐19 (OR 2.2, 95% CI: 0.2‐0.8; P = .0434), in comparison with the rest of the hospital population. Conclusion The prevalence of COVID‐19 in hospitalised patients with psychiatric disorders is increased compared with that of the general population; however, a lower mortality rate was detected. Also, an increased risk of COVID‐19 was detected in patients with comorbidities. Interestingly, the observed variation in COVID‐19 prevalence in patients with schizophrenia and intellectual disability was not associated with age or other specific medical diagnoses.

show abstract

Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19—A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium

Cited by 319 publications

References 50 publications

COVID-19 outcomes of 10,881 patients: retrospective study of neurological symptoms and associated manifestations (Philippine CORONA Study)

COVID-19 outcomes of 10,881 patients: retrospective study of neurological symptoms and associated manifestations (Philippine CORONA Study)

COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies

Patients with schizophrenia have decreased COVID‐19 prevalence among hospitalised patients with psychiatric and neurological diseases: A retrospective analysis in Mexican population

Contact Info

Product

Resources

About